Recent Company News

• 12:02 PM ET Apr 25, 2025
  

  Biophytis postpones publication of its annual financial statements; targets publication by end of May (€0.17, 0.00)

• 01:01 AM ET Apr 22, 2025
  

  Biophytis Targets Mobility Restoration in Patients with Obesity

• 01:31 AM ET Apr 09, 2025
  

  Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity

• 01:01 AM ET Apr 09, 2025
  

  Biophytis confirms the launch of the Phase 2 OBA clinical trial in obesity (€0.19, 0.00)

• 05:17 AM ET Mar 17, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:46 AM ET Mar 26, 2025
  

  Biophytis completes €2.6M private placement (€0.31, 0.00)

• 02:40 AM ET Mar 24, 2025
  

  Biophytis announces new preclinical results for its investigational drug BIO101 (€0.30, 0.00)

• 02:31 AM ET Mar 24, 2025
  

  Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity